Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

詳細情報 詳細情報について

• CRID

  1361699994343312000

• DOI

  10.1093/annonc/mdt012

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753419372990?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753419372990?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/24/6/1615/13788995/mdt012.pdf

• データソース種別

  • Crossref